Healthcare Biz Recap: Dendreon’s PREDICAMENT, Shionogi-ViiV’s TRIUMPH

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Shionogi-ViiV Healthcare, a joint venture comprising GlaxoSmithKline (NYSE:GSK), Pfizer (NYSE:PFE) and Shionogi, reports that a Phase III trial of its dolutegravir HIV treatment indicates that it could be more effective than Gilead’s (NASDAQ:GILD) and Bristol-Myers Squibb’s (NYSE:BMY) Atripla drug.

Don’t Miss: Are Traders NERVOUS About This Drug Stock?

Dendreon (NASDAQ:DNDN) closes in on its 52-week low, subsequent to being downgraded by Bank of America to Underperform, with its price target cut from $13 to $6. Sales of Provenge are anticipated to disappoint over the next several quarters, which will keep margins red, and worse, the valuation that an acquirer might be willing to pay will be constrained by the weak demand.

Don’t Miss: Will This Facebook Ad Plan Be a MEGA-HIT?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business